Tofflon Science and Technology Group (300171) Fair Value & Analysis
Healthcare · CN · Market cap 8.7B CNY
Analysis
Tofflon Science and Technology Group (300171) currently trades at ¥11.31, while our model-based Fair Value estimate is ¥8.78 — implying the stock looks roughly 22.4% overvalued today. We read business quality at 93/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
Tofflon Science and Technology Group Co., Ltd. engages in the research, development, production, sales, and services of pharmaceutical equipment in China and internationally. It operates through four segments: Biotechnology, Preparation Equipment, Engineering, and Food Engineering. The company offers technological research, such as cell technology, complex preparation, injection, and OSD laboratory; instruments, including cell therapy and nucleic acid drugs instruments, and table reactor; cryopreservation system for seeds and biological samples, and freeze-thaw system of biological stock solution; and single use technology, such as bioreactor, liquid distribution system, sterile bag, process chromatography, membrane filtration system, and others. It also provides culture medium, such as cell and gene therapy, biomacromolecule drugs, tobitec feeding medium, and other series; bioreactor and fermentation systems, cell factory, perfusion, and complementary systems; preparation systems, …
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.